Chronic Spontaneous Urticaria

Despite blood eosinophils depletion, benralizumab did not show a clinical benefit over placebo in chronic spontaneous urticaria, according to a phase 2b trial.

WASHINGTON — Urticaria activity symptom scores improved with barzolvolimab among patients with chronic spontaneous urticaria, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Is it an allergy or an autoimmune vasculitis, or a little of both? Find out the story of urticarial vasculitis, how this disease was recognized and eventually sorted out from other types of urticaria.

ANAHEIM, Calif. — Patients with inadequately controlled chronic spontaneous urticaria experienced relief of symptoms after only 2 weeks of treatment with remibrutinib, according to data from the ongoing REMIX-1 and REMIX-2 studies.

Tezspire reduced asthma exacerbations across all seasons, regardless of sensitivities to perennial and seasonal aeroallergens, a recent study showed.

ANAHEIM, Calif. — Patients using dupilumab with H1 antihistamines for their chronic spontaneous urticaria experienced greater improvements over 24 weeks than those on antihistamines alone, according to a recent study.

ANAHEIM, Calif. — A high proportion of chronic spontaneous urticaria cases remained uncontrolled despite antihistamine changes, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Patients with chronic spontaneous urticaria showed rapid symptom improvement with a favorable safety profile over 52 weeks of treatment with remibrutinib, according to a study published in The Journal of Allergy and Clinical Immunology.

In this edition, M-PDT efficacy similar to isotretinoin in acne vulgaris; Spitz neoplasm diagnosis in adults; immunotherapy treatment shows promise in basal cell carcinoma and more.

Positive top-line results from two phase 3 studies show remibrutinib yielded statistically significant improvements in disease severity among patients with chronic spontaneous urticaria, Novartis announced in a press release.